NSD3: A Promising Target for Cancer Therapy

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Nuclear receptor-binding SET domain protein 3 (NSD3) is a histone methyltransferase targeting H3K36.
• NSD3 plays a crucial role in regulating gene expression, genome imprinting, and genome stability.
• Aberrant NSD3 activity, through amplification, mutation, or fusion, is linked to various cancers.

Purpose of the Study:

• To review the structure, biological functions, and cancer relevance of NSD3.
• To analyze NSD3's role in the context of the hallmarks of cancer.
• To discuss the progress and challenges in developing NSD3-targeted cancer therapies.

Main Methods:

• Literature review of NSD3's structure, function, and involvement in cancer.
• Analysis of NSD3's role concerning established hallmarks of cancer.
• Examination of current research on NSD3 inhibitors and their clinical potential.

Main Results:

• NSD3's function as an H3K36 methyltransferase impacts key cellular processes.
• NSD3 is a significant factor in tumorigenesis, associated with multiple cancer types.
• Development of NSD3 inhibitors is a promising therapeutic strategy, though specificity remains a challenge.

Conclusions:

• NSD3 is a critical regulator in normal physiology and a key driver in cancer development.
• Targeting NSD3 offers a potential avenue for novel cancer treatments.
• Continued research into selective NSD3 inhibitors is essential for clinical advancement.